NON-SMALL CELL LUNG CANCER

This study is testing whether a combination of two new drugs can help control advanced non-small cell lung cancer that has specific genetic features (HER2 abnormalities). It will enroll about 30 adults, including those who have already tried standard treatment and those who have …

This early-stage study is testing a new drug called CKD-703 in people with advanced solid tumors, including a specific type of lung cancer. The drug is designed to target cancer cells more precisely to try to shrink tumors while potentially causing fewer side effects. The study w…

This study is testing if adding electro-acupuncture to standard first-line treatment helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 424 participants will be randomly assigned to receive either real or sham acupuncture a…

This study is for adults with advanced squamous non-small cell lung cancer who haven't had prior treatment. It compares two different drug combinations: a new drug called RC148 plus standard chemotherapy versus an existing drug called tislelizumab plus the same chemotherapy. The …

This study aims to see if giving the numbing medication lidocaine during and right after lung cancer surgery can help prevent the cancer from coming back or spreading. About 1,400 patients having minimally invasive surgery will be randomly assigned to receive either lidocaine or …

This study is testing if adding a special, condensed form of radiation therapy to a new immunotherapy drug and standard chemotherapy works better for people with advanced lung cancer. The goal is to see if this three-part combination can shrink tumors more effectively and help pa…

This study is testing if surgically removing the main lung tumor before starting the drug osimertinib works better than just taking the drug alone for people with advanced EGFR-mutant lung cancer. About 118 patients will be randomly assigned to either have surgery followed by the…

This early-stage study is testing a new radioactive antibody called LNTH-2403 in people with advanced colorectal, head and neck, lung, or breast cancer. The main goals are to see if a single dose is safe and to use special scans to see where the antibody goes in the body and if i…

This study is testing whether a personalized immune cell therapy can help prevent lung cancer from coming back after surgery. Doctors will take a patient's own immune cells from their tumor, grow more of them in a lab, and then infuse them back into the patient. The goal is to se…

This study is testing a new medicine called PF-08634404 to see if it can help adults with early-stage non-small cell lung cancer. The medicine will be given either alone or with chemotherapy, depending on whether the cancer can be removed with surgery. Researchers want to see if …

This study is testing if adding an inhaled drug called azacytidine to standard pre-surgery treatment can better fight early-stage lung cancer. The inhaled drug is designed to target the lungs directly with fewer side effects. About 60 adults with operable lung cancer will receive…

This study is testing a new type of targeted radiation therapy for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. Doctors will give patients a radioactive drug designed to seek out and deliver radiation directly to cancer cells…

This is the first study in humans testing a new cancer drug called QLS5316. Researchers want to find the safest dose and see if it helps control advanced solid tumors in patients who have run out of standard treatment options. The study will enroll 300 adults with various advance…

This study is testing a new oral drug called JYP0322 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change (ROS1-positive) and has stopped responding to previous targeted therapies. About 207 participants will be randomly assigned t…

This study is testing whether combining two drugs, chidamide and ivonescimab, can help control advanced non-small cell lung cancer that has started growing again after initially responding to immunotherapy. It will involve about 32 adults whose tumors show high levels of a specif…

This study is testing a new surgical technique for early-stage lung cancer. Surgeons will use a 3D virtual reality model of the patient's lungs, created from their scans, to plan and practice a precise, less invasive surgery to remove only the cancerous segment of the lung. The g…

This early-stage study is testing a new gene-editing treatment called EDB-102 for people with advanced lung cancer that has spread to the liver and stopped responding to standard drugs. The treatment uses CRISPR technology, delivered directly to the liver, to try to disable a spe…

This study is testing a new combination of drugs for people with a specific type of lung cancer. It's for patients whose non-small cell lung cancer has changed into a more aggressive small-cell type after their first treatment stopped working. The trial will see if adding a new t…

This study is testing whether adding a structured 12-week exercise program to standard immunotherapy can help patients with non-small cell lung cancer. It will compare two different types of exercise training to standard advice to see if exercise improves how well the cancer trea…

This early-stage study is testing if adding a cholesterol-lowering drug called pitavastatin to personalized chemotherapy can help control advanced non-small cell lung cancer that has stopped responding to standard treatments. Doctors will test tumor cells from each patient in a l…

This study is testing if surgically removing the main lung tumor before starting a combination of immunotherapy and chemotherapy leads to better outcomes for people with advanced lung cancer. About 118 patients will be randomly assigned to either have surgery first or just receiv…

This study is testing a new drug called TolueneSulfonamide for people with lung cancer who have fluid buildup around their lungs. Doctors will inject the drug directly into the chest to see if it's safe and if it helps reduce the fluid and breathing problems. The study will invol…

This study is testing if adding a fecal microbiota transplant (FMT) can improve treatment for certain stages of non-small cell lung cancer. The FMT comes from donors who responded well to a type of immunotherapy. The goal is to see if changing a patient's gut bacteria helps their…

This early-stage study is testing a new, highly focused type of radiation treatment called hypervision proton surgery for people with early, small lung cancer. The main goal is to see if giving one or two high doses of proton radiation is safe and can control the tumor. It will e…

This study is testing an experimental drug called SHR-1826 for people with advanced non-small cell lung cancer that has spread or can't be removed by surgery. About 90 participants who have already tried other treatments will receive the drug through an IV every three weeks. Rese…

This study is testing a new two-drug combination for people with advanced lung cancer that has worsened after standard treatments. It aims to find a safe and effective dose and see if the drugs can shrink tumors and control the disease. The trial will enroll about 120 adults who …

This global study is testing whether adding an experimental drug called plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. It's for patients whose cancer has worsened after trying immunotherapy and platinum-based che…

This study is for people with a specific type of lung cancer (EGFR-positive, non-squamous, stage II-IIIB) that can be removed with surgery. It will test if adding a new drug called SYS6010 to a standard drug (osimertinib) before surgery is more effective and safe than using the s…

This study aims to find the best initial treatment for patients with lung cancer that has spread to the brain but isn't causing symptoms. It will compare starting with precise radiation to all brain tumors followed by a new drug (ivonescimab) plus chemotherapy, versus starting wi…

This study is for people with advanced non-squamous non-small cell lung cancer that has worsened after previous treatment. Researchers want to see if a new two-drug combination (HS-20093 plus adebrelimab) works better and is safer than the standard chemotherapy drug docetaxel. Ab…

This study is testing a new approach for patients with a specific type of advanced lung cancer. Instead of starting with harsh chemotherapy and radiation, patients first receive a combination of two immunotherapy drugs to help their own immune system attack the cancer. After this…

This study is testing whether two different drug treatments can safely shrink lung tumors before surgery. It is for adults with a specific type of operable non-small cell lung cancer who have not had prior cancer treatment. The goal is to see if shrinking the tumor first leads to…

This study is testing an investigational drug called AK112 for people with advanced non-squamous lung cancer. It is for patients whose cancer has a specific genetic change and has stopped responding to standard targeted pills (TKIs). The main goal is to see if AK112 can shrink tu…

This study is testing whether a fecal microbiota transplant (FMT) can help a cancer immunotherapy drug work again for people with advanced non-small cell lung cancer. The treatment is for patients whose cancer has continued to grow despite previous immunotherapy. Researchers will…

This clinical trial is testing whether a new drug called SYS6090, when combined with standard chemotherapy or other targeted therapies, is safe and effective for people with advanced lung cancer. The study will enroll about 600 adults with either non-small cell or small cell lung…

This study is testing whether combining two targeted drugs, SHR-A1811 and pertuzumab, can help control advanced lung cancer that has a specific genetic change called HER2 and has worsened after at least one prior treatment. About 60 adults with this type of cancer will receive th…

This study is testing the safety and effectiveness of a new two-drug combination (ABSK043 plus glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It will enroll up to 86 adults who have either been previously treat…

This study compares an experimental drug called YL202 against the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). It's for patients whose cancer has continued to grow despite trying two other …

This study is for people with a specific type of advanced lung cancer that has stopped responding to standard treatments. It aims to see if a new drug called SYS6010 works better and is safer than the current chemotherapy drug, docetaxel. About 506 participants will be randomly a…

This study is testing a new two-drug combination for people with a specific type of advanced lung cancer that has spread. The goal is to find a safe dose and see if the combination can help shrink tumors or stop them from growing. The trial is for adults whose cancer has a geneti…

This is the first study in people to test a new drug called ITC-6146RO for patients with advanced or metastatic cancer who have run out of standard treatment options. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll about 102 a…

This early-stage study is testing whether combining two drugs works better for people with advanced lung cancer that has a specific genetic change (KRAS G12C) and has stopped responding to previous targeted treatments. The main goal is to check if the combination is safe and tole…

This study tests whether adding chemotherapy to the drug osimertinib helps control lung cancer that has spread to other parts of the body after initial treatment. The trial will enroll about 100 patients in China whose lung cancer returned despite previous surgery and medication.…

This study aims to see if giving a white blood cell booster drug (Leucogen) alongside a targeted cancer drug (pralsetinib) can prevent a common and serious side effect—low white blood cell counts—in patients with advanced lung cancer. It will enroll 25 adults with a specific gene…

This study is testing a new type of PET scan that uses a special tracer called 68Ga-TOI-1 to detect lung cancer. Researchers want to see if this new scan can better identify cancerous lung tumors and determine how far they've spread compared to current standard PET scans. The stu…

This study is testing a new computer tool that creates a 3D model of a patient's lungs before lung cancer surgery. Doctors will use this model to perform a 'virtual surgery' to predict how well the patient's lungs will work after the real operation. The goal is to give surgeons a…

This study aims to test a new method for predicting lung cancer risk and to see how well low-dose CT scans work for finding lung cancer in people who have never smoked. It will enroll 2,500 participants aged 40-80 with no smoking history. Participants will answer questionnaires, …

This is a first-in-human study to test the safety of a new imaging drug called [18F]DK222. The drug is designed to stick to a specific protein (PD-L1) on cancer cells, potentially making tumors show up more clearly on a PET/CT scan. The trial will enroll 6 adults with lung or bla…

This study is testing whether 3D models created from a standard CT scan (without contrast dye) are as accurate as models from a contrast CT scan for planning a precise type of lung cancer surgery. It will involve 50 adults with early-stage lung cancer who are eligible for minimal…

This study aims to see if a structured exercise program before surgery helps people with non-small cell lung cancer recover better. Researchers will have 62 participants either do two weeks of daily walking and breathing exercises before their operation or follow standard pre-sur…

This study aims to see if adding two existing medications—pentoxifylline and vitamin E—to standard lung cancer treatment can reduce lung damage caused by radiation therapy. Researchers will enroll 150 adults with stage III lung cancer who are receiving chemotherapy, radiation, an…

This study is testing whether a personalized exercise program is practical and acceptable for people with stage II-III lung cancer. It will involve about 20 participants who will follow the exercise plan before, during, and after their cancer treatment. The main goal is to see if…

This study is testing whether a supervised exercise program is safe and practical for people with lung cancer to do while they are receiving radiation and chemotherapy. It will involve 10 participants doing breathing exercises, walking or cycling, and light strength training duri…

This study is testing a special chatbot on the LINE app to see if it helps people with advanced lung cancer better manage the side effects of their oral medication. About 178 participants will be randomly assigned to receive either their usual care or usual care plus access to th…

This study is testing whether adding a medication called megestrol acetate to standard lung cancer treatment helps malnourished patients gain weight and improve their appetite. Researchers will compare weight gain, appetite, and cancer treatment outcomes between patients receivin…

This study aims to find out if a new blood test can predict which patients with advanced lung cancer will respond best to a standard combination of chemotherapy and immunotherapy. Researchers will measure specific immune cells in the blood of 80 patients before and during treatme…

This study aims to see how a non-invasive treatment called Tumor Treating Fields (TTFields) affects lung cancer cells before surgery. TTFields uses low-intensity electrical fields. The study will enroll 18 patients with early-stage lung cancer to check the safety of the treatment…

This study aims to understand how well a blood test can detect tiny amounts of leftover cancer DNA after surgery. It will follow 840 patients with breast, lung, prostate, ovarian, or gastric cancer to see if this 'liquid biopsy' can predict if the cancer might come back. The stud…

This study aims to see if a blood test can predict which patients with advanced lung cancer or melanoma will respond to a common type of immunotherapy. Researchers will analyze tiny particles in the blood of 378 patients before and during their standard treatment. The goal is to …

This study aims to learn about the real-world safety and effectiveness of the immunotherapy drug adebrelimab in people with advanced solid tumors, primarily lung and gastrointestinal cancers. It will observe 300 patients who have already decided with their doctor to receive this …